Robust metabolic adaptation underlying tumor progression

Metabolomics

Volumn 4, Issue 1, 2008, Pages 1-12

  Vizán, Pedro ^a   Mazurek, Sybille ^b,c   Cascante, Marta ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c ScheBo Biotech AG   (Germany)

Author keywords

Acidosis and tumor progression; Alternative to glycolytic energy conversion; Biosynthetic pathways in tumoral metabolism; Isoenzyme expression in tumor cells; Regulation of glucose metabolism in tumors; Tumor metabolism; Tumor metabolism and apoptosis; Warburg effect

Indexed keywords

EID: 38949107594     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-007-0101-3     Document Type: Review

References (143)

1. Aderem, A. (2005). Systems biology: Its practice and challenges. Cell, 121, 511-513.
2. Arora, K. K., & Pedersen, P. L. (1988). Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. Journal of Biological Chemistry, 263, 17422-17428.
3. Ashrafian, H. (2006). Cancer's sweet tooth: The Janus effect of glucose metabolism in tumorigenesis. Lancet, 367, 618-621.
4. Bensaad, K., Tsuruta, A., Selak, M. A., et al. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 126, 107-120.
5. Boros, L. G., Cascante, M., & Paul Lee, W.-N. (2002). Metabolic profiling of cell growth and death in cancer: Applications in drug discovery. Drug Discovery Today, 7, 364-372.
6. Boros, L. G., Lee, P. W. N., Brandes, J. L., et al. (1998). Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: Is cancer a disease of cellular glucose metabolism? Medical Hypotheses, 50, 55-59.
7. Boros, L. G., Puigjaner, J., Cascante, M., et al. (1997). Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Research, 57, 4242-4248.
8. Brahimi-Horn, M. C., Chiche, J., & Pouyssegur, J. (2007). Hypoxia signalling controls metabolic demand. Current Opinion in Cell Biology, 19, 223-229.
9. Brusselmans, K., De Schrijver, E., Verhoeven, G., & Swinnen, J. V. (2005). RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Research, 65, 6719-6725.
10. Bui, T., & Thompson, C. B. (2006). Cancer's sweet tooth. Cancer Cell, 9, 419-420.
11. Burt, B. M., Humm, J. L., Kooby, D. A., et al. (2001). Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia, 3, 189-195.
12. Bustamante, E., Pediaditakis, P., He, L., & Lemasters, J. J. (2005). Isolated mouse liver mitochondria are devoid of glucokinase. Biochemical and Biophysical Research Communications, 334, 907-910.
13. Carujo, S., Estanyol, J. M., Ejarque, A., et al. (2006). Glyceraldehyde 3-phosphate dehydrogenase is a SET-binding protein and regulates cyclin B-cdk1 activity. Oncogene, 25, 4033-4042.
14. Cascante, M., Boros, L. G., Comin-Anduix, B., et al. (2002). Metabolic control analysis in drug discovery and disease. Nature Biotechnology, 20, 243-249.
15. Cascante, M., Centelles, J. J., Veech, R. L., Lee, W. N., & Boros, L. G. (2000). Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation. Nutrition and Cancer, 36, 150-154.
16. Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2, 563-572.
17. Cho, C. R., Labow, M., Reinhardt, M., van Oostrum, J., & Peitsch, M. C. (2006). The application of systems biology to drug discovery. Current Opinion in Chemical Biology, 10, 294-302.
18. Claudino, W. M., Quattrone, A., Biganzoli, L., et al. (2007). Metabolomics: Available results, current research projects in breast cancer, and future applications. Journal of Clinical Oncology, 25, 2840-2846.
19. Coy, J. F., Dressler, D., Wilde, J., & Schubert, P. (2005). Mutations in the transketolase-like gene TKTL1: Clinical implications for neurodegenerative diseases, diabetes and cancer. Clinical Laboratory, 51, 257-273.
20. Czernin, J., & Phelps, M. E. (2002). Positron emission tomography scanning: Current and future applications. Annual Review of Medicine, 53, 89-112.
21. Dang, C. V., & Semenza, G. L. (1999). Oncogenic alterations of metabolism. Trends in Biochemical Sciences, 24, 68-72.
22. Danial, N. N., Gramm, C. F., Scorrano, L., et al. (2003). BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature, 424, 952-956.
23. Dastoor, Z., & Dreyer, J. L. (2001). Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. Journal of Cell Science, 114, 1643-1653.
24. Denkert, C., Budczies, J., Kind, T., et al. (2006). Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Research, 66, 10795-10804.
25. Dennis, P. B., Jaeschke, A., Saitoh, M., et al. (2001). Mammalian TOR: A homeostatic ATP sensor. Science, 294, 1102-1105.
26. De Schrijver, E., Brusselmans, K., Heyns, W., Verhoeven, G., & Swinnen, J. V. (2003). RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Research, 63, 3799-3804.
27. Downward, J. (2003). Cell biology: Metabolism meets death. Nature, 424, 896-897.
28. Eigenbrodt, E., Fister, P., & Reinacher, M. (1985). New perspectives on carbohydrate metabolism in tumor cells. In R. Beitner (Ed.), Regulation of carbohydrate metabolism. Florida: CRC Press.
29. Elstrom, R. L., Bauer, D. E., Buzzai, M., et al. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Research, 64, 3892-3899.
30. Engel, R. H., & Evens, A. M. (2006). Oxidative stress and apoptosis: A new treatment paradigm in cancer. Frontiers in Bioscience, 11, 300-312.
31. Engel, M., Mazurek, S., Eigenbrodt, E., & Welter, C. (2004). Phosphoglycerate mutase-derived polypeptide inhibits glycolytic flux and induces cell growth arrest in tumor cell lines. Journal of Biological Chemistry, 279, 35803-35812.
32. Fantin, V. R., St-Pierre, J., & Leder, P. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 9, 425-434.
33. Gambhir, S. S. (2002). Molecular imaging of cancer with positron emission tomography. Nature Reviews Cancer, 2, 683-693.
34. Garber, K. (2006). Energy deregulation: Licensing tumors to grow. Science, 312, 1158-1159.
35. Gatenby, R. A., Gawlinski, E. T., Gmitro, A. F., Kaylor, B., & Gillies, R. J. (2006). Acid-mediated tumor invasion: A multidisciplinary study. Cancer Research, 66, 5216-5223.
36. Gatenby, R. A., & Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? Nature Reviews Cancer, 4, 891-899.
37. German, J. B., Hammock, B. D., & Watkins, S. M. (2005). Metabolomics: Building on a century of biochemistry to guide human health. Metabolomics, 1, 3-9.
38. Gottfried, E., Kunz-Schughart, L. A., Ebner, S., et al. (2006). Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood, 107, 2013-2021.
39. Gottlieb, E., & Tomlinson, I. P. (2005). Mitochondrial tumour suppressors: A genetic and biochemical update. Nature Reviews Cancer, 5, 857-866.
40. Grimm, H., Tibell, A., Norrlind, B., et al. (1994). Immunoregulation by parenteral lipids: Impact of the n-3 to n-6 fatty acid ratio. JPEN Journal of Parenteral and Enteral Nutrition, 18, 417-421.
41. Gu, J., Yamamoto, H., Fukunaga, H., et al. (2006). Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Digestive Diseases and Sciences, 51, 2198-2205.
42. Gunsalus, I. C., Horecker, B. L., & Wood, W. A. (1955). Pathways of carbohydrate metabolism in microorganisms. Bacteriological Reviews, 19, 79-128.
43. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57-70.
44. Hansen, M., Le Nours, J., Johansson, E., et al. (2004). Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Science, 13, 1031-1042.
45. Hatzivassiliou, G., Zhao, F., Bauer, D. E., et al. (2005). ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 8, 311-321.
46. Hawkins, R. A., & Phelps, M. E. (1988). PET in clinical oncology. Cancer Metastasis Reviews, 7, 119-142.
47. Hegde, P., Qi, R., Gaspard, R., et al. (2001). Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Research, 61, 7792-7797.
48. Hewitson, K. S., Lienard, B. M., McDonough, M. A., et al. (2007). Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. Journal of Biological Chemistry, 282, 3293-3301.
49. Horecker, B. L. (2002). The pentose phosphate pathway. Journal of Biological Chemistry, 277, 47965-47971.
50. Hornberg, J. J., Bruggeman, F. J., Westerhoff, H. V., & Lankelma, J. (2006). Cancer: A systems biology disease. Biosystems, 83, 81-90.
51. Ignacak, J., & Stachurska, M. B. (2003). The dual activity of pyruvate kinase type M2 from chromatin extracts of neoplastic cells. Comparative Biochemistry and Physiology. Part B, Biochemistry and Molecular Biology, 134, 425-433.
52. Isaacs, J. S., Jung, Y. J., Mole, D. R., et al. (2005). HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell, 8, 143-153.
53. Ishii, N., Ishii, T., & Hartman, P. S. (2007). The role of the electron transport SDHC gene on lifespan and cancer. Mitochondrion, 7, 24-28.
54. Jeong, D. W., Kim, T. S., Cho, I. T., & Kim, I. Y. (2004). Modification of glycolysis affects cell sensitivity to apoptosis induced by oxidative stress and mediated by mitochondria. Biochemical and Biophysical Research Communications, 313, 984-991.
55. Jones, R. G., Plas, D. R., Kubek, S., et al. (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Molecular Cell, 18, 283-293.
56. Jordan, K. W., & Cheng, L. L. (2007). NMR-based metabolomics approach to target biomarkers for human prostate cancer. Expert Review of Proteomics, 4, 389-400.
57. Kell, D. B. (2006). Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discovery Today, 11, 1085-1092.
58. Kim, J. W., & Dang, C. V. (2005). Multifaceted roles of glycolytic enzymes. Trends in Biochemical Sciences, 30, 142-150.
59. Kim, J. W., & Dang, C. V. (2006). Cancer's molecular sweet tooth and the Warburg effect. Cancer Research, 66, 8927-8930.
60. Kim, K. H., Rodriguez, A. M., Carrico, P. M., & Melendez, J. A. (2001). Potential mechanisms for the inhibition of tumor cell growth by manganese superoxide dismutase. Antioxidants & Redox Signaling, 3, 361-373.
61. Kim, J. W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism, 3, 177-185.
62. King, A., Selak, M. A., & Gottlieb, E. (2006). Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene, 25, 4675-4682.
63. Kitano, H. (2002). Systems biology: A brief overview. Science, 295, 1662-1664.
64. Koivunen, P., Hirsila, M., Remes, A. M., et al. (2007). Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: Possible links between cell metabolism and stabilization of HIF. Journal of Biological Chemistry, 282, 4524-4532.
65. Kondoh, H., Lleonart, M. E., Gil, J., et al. (2005). Glycolytic enzymes can modulate cellular life span. Cancer Research, 65, 177-185.
66. Kress, S., Stein, A., Maurer, P., et al. (1998). Expression of hypoxia-inducible genes in tumor cells. Journal of Cancer Research and Clinical Oncology, 124, 315-320.
67. Krockenberger, M., Honig, A., Rieger, L., et al. (2007). Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. International Journal of Gynecological Cancer, 17, 101-106.
68. Kuhajda, F. P. (2006). Fatty acid synthase and cancer: New application of an old pathway. Cancer Research, 66, 5977-5980.
69. Kuo, W., Lin, J., & Tang, T. K. (2000). Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. International Journal of Cancer, 85, 857-864.
70. Langbein, S., Zerilli, M., Zur Hausen, A., et al. (2006). Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. British Journal of Cancer, 94, 578-585.
71. Liu, E. T. (2005). Systems biology, integrative biology, predictive biology. Cell, 121, 505-506.
72. Lobo, C., Ruiz-Bellido, M. A., Aledo, J. C., et al. (2000). Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochemical Journal, 348(Pt 2), 257-261.
73. Loffler, M., Fairbanks, L. D., Zameitat, E., Marinaki, A. M., & Simmonds, H. A. (2005). Pyrimidine pathways in health and disease. Trends in Molecular Medicine, 11, 430-437.
74. Lu, H., Forbes, R. A., & Verma, A. (2002). Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. Journal of Biological Chemistry, 277, 23111-23115.
75. Macheda, M. L., Rogers, S., & Best, J. D. (2005). Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of Cellular Physiology, 202, 654-662.
76. Mack, F. A., Rathmell, W. K., Arsham, A. M., et al. (2003). Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell, 3, 75-88.
77. Majewski, N., Nogueira, V., Bhaskar, P., et al. (2004a). Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Molecular Cell, 16, 819-830.
78. Majewski, N., Nogueira, V., Robey, R. B., & Hay, N. (2004b). Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Molecular and Cellular Biology, 24, 730-740.
79. Majumder, P. K., Febbo, P. G., Bikoff, R., et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine, 10, 594-601.
80. Malaisse-Lagae, F., & Malaisse, W. J. (1988). Hexose metabolism in pancreatic islets: Regulation of mitochondrial hexokinase binding. Biochemical Medicine and Metabolic Biology, 39, 80-89.
81. Malyankar, U. M. (2007). Tumor-associated antigens and biomarkers in cancer and immune therapy. International Reviews of Immunology, 26, 223-247.
82. Mates, J. M., & Sanchez-Jimenez, F. M. (2000). Role of reactive oxygen species in apoptosis: Implications for cancer therapy. International Journal of Biochemistry and Cell Biology, 32, 157-170.
83. Matoba, S., Kang, J. G., Patino, W. D., et al. (2006). p53 regulates mitochondrial respiration. Science, 312, 1650-1653.
84. Mazurek, S., Boschek, C. B., Hugo, F., & Eigenbrodt, E. (2005). Pyruvate kinase type M2 and its role in tumor growth and spreading. Seminars in Cancer Biology, 15, 300-308.
85. Mazurek, S., & Eigenbrodt, E. (2003). The tumor metabolome. Anticancer Research, 23, 1149-1154.
86. Menendez, J. A., Vellon, L., & Lupu, R. (2005). Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: Blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Annals of Oncology, 16, 1253-1267.
87. Morita, T., Nagaki, T., Fukuda, I., & Okumura, K. (1992). Clastogenicity of low pH to various cultured mammalian cells. Mutation Research, 268, 297-305.
88. Morvan, D., & Demidem, A. (2007). Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Research, 67, 2150-2159.
89. Nutt, L. K., Margolis, S. S., Jensen, M., et al. (2005). Metabolic regulation of oocyte cell death through the CaMKII-mediated phosphorylation of caspase-2. Cell, 123, 89-103.
90. Ockner, R. K. (2004). Integration of metabolism, energetics, and signal transduction. New York: Kluwer Academic/Plenum Publishers.
91. Oksman-Caldentey, K. M., & Saito, K. (2005). Integrating genomics and metabolomics for engineering plant metabolic pathways. Current Opinion in Biotechnology, 16, 174-179.
92. Oltvai, Z. N., & Barabasi, A. L. (2002). Systems biology. Life's complexity pyramid. Science, 298, 763-764.
93. Osthus, R. C., Shim, H., Kim, S., et al. (2000). Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. Journal of Biological Chemistry, 275, 21797-21800.
94. Ott, K. H., Aranibar, N., Singh, B., & Stockton, G. W. (2003). Metabonomics classifies pathways affected by bioactive compounds. Artificial neural network classification of NMR spectra of plant extracts. Phytochemistry, 62, 971-985.
95. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006). HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism, 3, 187-197.
96. Park, H. J., Lyons, J. C., Ohtsubo, T., & Song, C. W. (2000). Cell cycle progression and apoptosis after irradiation in an acidic environment. Cell Death and Differentiation, 7, 729-738.
97. Pelicano, H., Carney, D., & Huang, P. (2004). ROS stress in cancer cells and therapeutic implications. Drug Resistance Updates, 7, 97-110.
98. Pelicano, H., Xu, R. H., Du, M., et al. (2006). Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. Journal of Cell Biology, 175, 913-923.
99. Perez-Gomez, C., Campos-Sandoval, J. A., Alonso, F. J., et al. (2005). Co-expressionof glutaminase K and L isoenzymes in human tumour cells. Biochemical Journal, 386, 535-542.
100. Pfeiffer, T., Schuster, S., & Bonhoeffer, S. (2001). Cooperation and competition in the evolution of ATP-producing pathways. Science, 292, 504-507.
101. Pierens, G. K., Palframan, M. E., Tranter, C. J., Carroll, A. R., & Quinn, R. J. (2005). A robust clustering approach for NMR spectra of natural product extracts. Magnetic Resonance in Chemistry, 43, 359-365.
102. Plas, D. R., & Thompson, C. B. (2005). Akt-dependent transformation: There is more to growth than just surviving. Oncogene, 24, 7435-7442.
103. Porstmann, T., Griffiths, B., Chung, Y. L., et al. (2005). PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene, 24, 6465-6481.
104. Pouyssegur, J., Dayan, F., & Mazure, N. M. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 441, 437-443.
105. Purcell, W. T., & Ettinger, D. S. (2003). Novel antifolate drugs. Current Oncology Reports, 5, 114-125.
106. Raamsdonk, L. M., Teusink, B., Broadhurst, D., et al. (2001). A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nature Biotechnology, 19, 45-50.
107. Racker, E. (1974). History of the Pasteur effect and its pathobiology. Molecular and Cellular Biochemistry, 5, 17-23.
108. Rais, B., Comin, B., Puigjaner, J., et al. (1999). Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Letters, 456, 113-118.
109. Ramanathan, A., Wang, C., & Schreiber, S. L. (2005). Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proceedings of the National Academy of Science USA, 102, 5992-5997.
110. Ramos-Montoya, A., Lee, W. N., Bassilian, S., et al. (2006). Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. International Journal of Cancer, 119, 2733-2741.
111. Rathmell, J. C., Fox, C. J., Plas, D. R., et al. (2003). Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Molecular and Cellular Biology, 23, 7315-7328.
112. Rimpi, S., & Nilsson, J. A. (2007). Metabolic enzymes regulated by the Myc oncogene are possible targets for chemotherapy or chemoprevention. Biochemical Society Transactions, 35, 305-310.
113. Robey, R. B., & Hay, N. (2006). Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene, 25, 4683-4696.
114. Rossignol, R., Gilkerson, R., Aggeler, R., et al. (2004). Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Research, 64, 985-993.
115. Ruiz-Lozano, P., Hixon, M. L., Wagner, M. W., et al. (1999). p53 is a transcriptional activator of the muscle-specific phosphoglycerate mutase gene and contributes in vivo to the control of its cardiac expression. Cell Growth and Differentiation, 10, 295-306.
116. Schafer, D., Hamm-Kunzelmann, B., & Brand, K. (1997). Glucose regulates the promoter activity of aldolase A and pyruvate kinase M2 via dephosphorylation of Sp1. FEBS Letters, 417, 325-328.
117. Schmidt, C. W. (2004). Metabolomics: What's happening downstream of DNA. Environmental Health Perspectives, 112, A410-A415.
118. Selak, M. A., Armour, S. M., MacKenzie, E. D., et al. (2005). Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85.
119. Semenza, G. L., Artemov, D., Bedi, A., et al. (2001). 'The metabolism of tumours': 70 years later. Novartis Foundation Symposium, 240, 251-260; discussion 260-264.
120. Shi, Q., Le, X., Wang, B., et al. (2001). Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene, 20, 3751-3756.
121. Shim, H., Chun, Y. S., Lewis, B. C., & Dang, C. V. (1998). A unique glucose-dependent apoptotic pathway induced by c-Myc. Proceedings of the National Academy of Science USA, 95, 1511-1516.
122. Shim, H., Dolde, C., Lewis, B. C., et al. (1997). c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proceedings of the National Academy of Science USA, 94, 6658-6663.
123. Sirover, M. A. (1999). New insights into an old protein: The functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochimica et Biophysica Acta, 1432, 159-184.
124. Spittler, A., Oehler, R., Goetzinger, P., et al. (1997). Low glutamine concentrations induce phenotypical and functional differentiation of U937 myelomonocytic cells. Journal of Nutrition, 127, 2151-2157.
125. Staiger, W. I., Coy, J. F., Grobholz, R., et al. (2006). Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncology Reports, 16, 657-661.
126. Stern, R., Shuster, S., Neudecker, B. A., & Formby, B. (2002). Lactate stimulates fibroblast expression of hyaluronan and CD44: The Warburg effect revisited. Experimental Cell Research, 276, 24-31.
127. Stetak, A., Veress, R., Ovadi, J., et al. (2007). Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Research, 67, 1602-1608.
128. Swinnen, J. V., Brusselmans, K., & Verhoeven, G. (2006). Increased lipogenesis in cancer cells: New players, novel targets. Current Opinion in Clinical Nutrition and Metabolic Care, 9, 358-365.
129. Trujillo, E., Davis, C., & Milner, J. (2006). Nutrigenomics, proteomics, metabolomics, and the practice of dietetics. Journal of the American Dietetic Association, 106, 403-413.
130. Urbanczyk-Wochniak, E., Luedemann, A., Kopka, J., et al. (2003). Parallel analysis of transcript and metabolic profiles: A new approach in systems biology. EMBO Reports, 4, 989-993.
131. van der Greef, J., Hankemeier, T., & McBurney, R. N. (2006). Metabolomics-based systems biology and personalized medicine: Moving towards n = 1 clinical trials? Pharmacogenomics, 7, 1087-1094.
132. Vizan, P., Boros, L. G., Figueras, A., et al. (2005). K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Research, 65, 5512-5515.
133. Vrablic, A. S., Albright, C. D., Craciunescu, C. N., Salganik, R. I., & Zeisel, S. H. (2001). Altered mitochondrial function and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes. FASEB Journal, 15, 1739-1744.
134. Walenta, S., Schroeder, T., & Mueller-Klieser, W. (2004). Lactate in solid malignant tumors: Potential basis of a metabolic classification in clinical oncology. Current Medicinal Chemistry, 11, 2195-2204.
135. Wallace, D. C. (2005). Mitochondria and cancer: Warburg addressed. Cold Spring Harbor Symposia on Quantitative Biology, 70, 363-374.
136. Warburg, O., Posener, K., & Negelein, E. (1924). Über den Stoffwechsel der Karzinomzellen. Biochemische Zeitschrift, 152, 309-344.
137. Weber, W. A., Avril, N., & Schwaiger, M. (1999). Relevance of positron emission tomography (PET) in oncology. Strahlentherapie und Onkologie, 175, 356-373.
138. Williams, A. C., Collard, T. J., & Paraskeva, C. (1999). An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: Implications for clonal selection during colorectal carcinogenesis. Oncogene, 18, 3199-3204.
139. Xu, R. H., Pelicano, H., Zhou, Y., et al. (2005). Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Research, 65, 613-621.
140. Yang, N. S., Shyur, L. F., Chen, C. H., Wang, S. Y., & Tzeng, C. M. (2004). Medicinal herb extract and a single-compound drug confer similar complex pharmacogenomic activities in mcf-7 cells. Journal of Biomedical Science, 11, 418-422.
141. Yasuda, S., Arii, S., Mori, A., et al. (2004). Hexokinase II and VEGF expression in liver tumors: Correlation with hypoxia-inducible factor 1 alpha and its significance. Journal of Hepatology, 40, 117-123.
142. Zhang, S., Yang, J. H., Guo, C. K., & Cai, P. C. (2007). Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Letters, 253, 108-114.
143. Zu, X. L., & Guppy, M. (2004). Cancer metabolism: Facts, fantasy, and fiction. Biochemical and Biophysical Research Communications, 313, 459-465.